Please assess the completion status of the following clinical trial:

Trial Title: ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent signed prior to the performance of any study procedures~* Male or female volunteers, age 18 to 65 years, inclusive~* Overweight to obese (greater than or equal to BMI 28.0~* Magnetic resonance imaging derived proton density fat fraction (MRI-PDFF) ≥ 10%~* If subject has Type 2 diabetes mellitus (T2DM), on stable regimen, for at least 3 months prior to screening, of any combination (1) diet and exercise, (2) metformin with absent or mild gastrointestinal symptoms (nausea, vomiting or diarrhea), and/or (3) sodium glucose cotransporter-2 (SGLT-2) therapy~Exclusion Criteria:~* Women who are pregnant or breastfeeding~* Type 1 DM and/or insulin-dependent T2DM, or uncontrolled T2DM defined as HbA1c ≥ 9.5%~* History of pancreatitis or hypersensitivity reaction to GLP-1 analogues

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- ALT-801 Dose Level 1 (Type: EXPERIMENTAL): Administered once a week for 12 weeks
- ALT-801 Dose Level 2 (Type: EXPERIMENTAL): Administered once a week for 12 weeks
- ALT-801 Dose Level 3 (Type: EXPERIMENTAL): Administered once a week for 12 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Administered once a week for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).